Investing

Biogen, 3D Systems, Duke Energy, Ford and More of Friday Afternoon's Analyst Calls

Thinkstock

With the trading day practically over, the broad markets were sliding into the weekend. The S&P 500, Dow Jones industrial average, and Nasdaq are each posting losses over 1% as Friday comes to a close.

24/7 Wall St. is looking at some big analyst calls that we have seen so far on Thursday. We have included the most recent analyst call on each stock, as well as a recent trading history and the general consensus among analysts.

For those that might have missed it, 24/7 Wall St. had an earlier round of analyst calls on Friday that included Boeing, Goldman Sachs, NRG, Stich Fix, and more.

Akebia Therapeutics, Inc. (NASDAQ: AKBA) was downgraded by JPMorgan to an Underweight rating from Neutral. The stock was last seen at $3.28, in a 52-week range of $2.09 to $13.71. The consensus price target is $7.00.

Biogen Inc. (NASDAQ: BIIB) was upgraded to a Buy rating from Hold and its price target was raised to $358 from $258 at Stifel. The stock was trading at $284.98, in a 52-week trading range of $223.25 to $374.99. The consensus price target is $293.76.

3D Systems Corp. (NYSE: DDD) was downgraded to Hold from Buy at Craig Hallum. The consensus price target is $80.20. Shares traded at $26.68, in the 52-week range of $4.60 to $44.17.

Duke Energy Corp. (NYSE: DUK) was upgraded at KeyBanc Capital Markets to Overweight from Sector Perform with a price target of $106. The shares traded at $94.11, within its 52-week range of $62.13 to $103.79. Analysts have a consensus price target of $99.82.

Ford Motor Co. (NYSE: F) was downgraded to Underweight from Equal Weight at Morgan Stanley. The consensus target is $9.72. The stock traded at $10.60, in a 52-week range of $3.96 to $12.15.

Harley-Davidson, Inc. (NYSE: HOG) was downgraded to a Neutral rating from Buy at Northcoast. The stock was up about 1% to $40.57 a share on Friday. The 52-week range is $14.31 to $43.47. The consensus price target is $40.40.

Lexicon Pharma Inc. (NASDAQ: LXRX) was upgraded to Neutral from Underweight with a $7 price target at JPMorgan. Wedbush downgraded to a Neutral rating from Outperform with an $8 price target. The stock traded at $7.98 and has a consensus price target of $6.00. The 52-week trading range is $1.03 to $9.40.

PulteGroup, Inc. (NYSE: PHM) was upgraded to a Buy rating from Neutral at BTIG Research, also it was issued a $56 price target. The stock was last seen at $43.72, and it has a consensus target of $55.93. The 52-week trading range is $17.12 to $50.23.

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) was initiated with a Buy rating and a $26 price target at B. Riley Securities. The stock was trading at $28.67, in a 52-week range of $1.55 to $19.39. The consensus price target is $28.67.

Vail Resorts Inc. (NYSE: MTN) was initiated with a Neutral rating and a $290 price target at JPMorgan. Shares traded at $266.31, in a 52-week range of $125.00 to $300.00. The consensus price target is $279.60.

The #1 Thing to Do Before You Claim Social Security (Sponsor)

Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.

A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.

Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.

 

Have questions about retirement or personal finance? Email us at [email protected]!

By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.

By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.